CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse Other stock markets 21:00:02 08/05/2026 BST			5-day change	1st Jan Change
177.62 ^USD	-2.23%		+7.14%	-10.96%

05-08	Charles River Laboratories International, Inc. Seeks M&A Opportunities	CI
05-07	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI

Transcript : Charles River Laboratories International, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 10

Published on 03/10/2026 at 04:35 pm GMT - Modified on 03/16/2026 at 08:43 am GMT

S&P Capital IQ

Presenter Speech
Luke Sergott (Analysts)

All right. Good morning, everybody. It's Luke Sergott from Barclays. I cover life science tools and diagnostics. With me, I have my pleasure, Jim Foster, CEO of

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Charles River Laboratories International, Inc.

05-08	Charles River Laboratories International, Inc. Seeks M&A Opportunities	CI
05-07	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
05-07	Charles River Laboratories International, Inc., Q1 2026 Earnings Call, May 07, 2026
05-07	Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026	CI
05-07	Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance	MT
05-07	(CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08	MT
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q1 Adjusted EPS $2.06 per Share, vs. FactSet Est of $1.94	MT
05-07	Charles River beats quarterly estimates on steady demand for drug development services	RE
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M	MT
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M	MT
05-07	Charles River Laboratories International, Inc. Reports Consolidated Impairment Charges Results for the Quarter Ended March 28, 2026	CI
05-07	Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026	CI
04-30	Charles River Laboratories Launches Rat in Vitro Fertility Services	CI
04-14	Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says	MT
04-14	Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $200, Maintains Overweight Rating	MT